Our #BaseEditing paper is DG-GT’s “Paper of the Quarter”! 🎉

We used precise gene editing to correct cancer mutations in TP53 – and watched as corrected cells nearly vanished. A step toward mRNA therapies for cancer! 💡

Full paper: rdcu.be/exqtH #CancerResearch #GeneEditing #Science #DG_GT

Our lab shone at EMBO Workshop CRISPR-Cas: From Biology to Therapeutic Applications in Sorrento! Haidy presented her award-winning poster on modulating anti-tumor efficacy & T cell exhaustion! 🏆Frank shared insights on developing a BE platform for cancer research. #CRISPR #EMBO #Science #GeneEditing

We’re live! The Buchholz Lab’s 'CanCorrect' project has begun, funded by a BMFTR VIP+ grant. This grant will help us take our research to the next level, with the goal of advancing personalized cancer therapy. #CancerResearch #CRISPR #Science #Innovation #BMFTR

Shaping the future of healthcare! Frank Buchholz was part of the German Federal Ministry of Health’s event in Berlin to discuss ATMP Innovation Centers. Exciting discussions on how advanced therapies can transform patient care. #Innovation #Healthcare #ATMP #FutureOfMedicine #CarstenMüller-Tidow

Rewriting the Code of Life: A “The Scientist Speaks” podcast with Frank Buchholz on programmable recombinases

Tune in to hear Frank’s insights and discover how this innovation is shaping the future of medicine and beyond!

🎉 Buchholz Lab's new study uses base editing to target TP53 mutations in cancer! We fixed mutations in various cell lines, revealing key insights for precision therapies. Big congrats to our team! 👏 Read more here 🔗 kurzlinks.de/p9r6

Frank Buchholz has been awarded the ERC Advanced Grant for groundbreaking research on genome editing a second time! 🎉 His project titled “DNA-binding domain Conditioned Precision Genome Editing” has been selected for funding!